Literature DB >> 25962611

Randomized trial of anaesthetic interventions in external cephalic version for breech presentation.

K S Khaw1, S W Y Lee2, W D Ngan Kee3, L W Law4, T K Lau4, F F Ng3, T Y Leung4.   

Abstract

BACKGROUND: Successful external cephalic version (ECV) for breech presenting fetus reduces the need for Caesarean section (CS). We aimed to compare the success rate of ECV with either spinal anaesthesia (SA) or i.v. analgesia using remifentanil.
METHODS: In a double-phased, stratified randomized blinded controlled study we compared the success rates of ECV, performed under spinal anaesthesia (SA), i.v. analgesia (IVA) using remifentanil or no anaesthetic interventions. In phase I, 189 patients were stratified by parity before randomization to ECV, performed by blinded operators, under SA using either hyperbaric bupivacaine 9 mg with fentanyl 15 µg, i.v. remifentanil infusion 0.1 µg kg min(-1), or Control (no anaesthetic intervention). Operators performing ECV were blinded to the treatment allocation. In phase 2, patients in the Control group in whom the initial ECV failed were further randomized to receive either SA (n=9) or IVA (n=9) for a re-attempt. The primary outcome was the incidence of successful ECV.
RESULTS: The success rate in Phase 1 was greatest using SA [52/63 (83%)], compared with IVA [40/63 (64%)] and Control [40/63 (64%)], (P=0.027). Median [IQR] pain scores on a visual analogue scale (range 0-100), were 0 [0-0] with SA, 35 [0-60] with IVA and 50 [30-75] in the Control group (P<0.001). Median [IQR] VAS sedation scores were highest with IVA [75 (50-80)], followed by SA, [0 (0-50)] and Control [0 (0-0)]. In phase 2, 7/9 (78%) of ECV re-attempts were successful with SA, whereas all re-attempts using IVA failed (P=0.0007). The incidence of fetal bradycardia necessitating emergency CS within 30 min, was similar among groups; 1.6% (1/63) in the SA and IVA groups and 3.2% (2/63) in the Control group.
CONCLUSIONS: SA increased the success rate and reduced pain for both primary and re-attempts of ECV, whereas IVA using remifentanil infusion only reduced the pain. There was no significant increase in the incidence of fetal bradycardia or emergency CS, with ECV performed under anaesthetic interventions. Relaxation of the abdominal muscles from SA appears to underlie the improved outcomes for ECV.
© The Author 2015. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  anesthesia regional; anesthesia, spinal; breech presentation; external cephalic version; obstetrics; remifentanil, analgesia, obstetric; term birth

Mesh:

Substances:

Year:  2015        PMID: 25962611     DOI: 10.1093/bja/aev107

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Neuraxial block and success of external cephalic version.

Authors:  C F Weiniger; V Rabkin
Journal:  BJA Educ       Date:  2020-07-18

2.  Sedation with Propofol plus Paracetamol in External Cephalic Version: An Observational Study.

Authors:  Javier Sánchez-Romero; Jesús López-Pérez; Ana Belén Flores-Muñoz; María Josefa Méndez-Martínez; Fernando Araico-Rodríguez; Jaime Mendiola-Olivares; José Eliseo Blanco-Carnero; Luis Falcón-Araña; Aníbal Nieto-Díaz; María Luisa Sánchez-Ferrer
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

3.  Anesthesia efficacy of bupivacaine in pregnant participants with breech presentation receiving external cephalic version: A protocol of systematic review of randomized controlled trials.

Authors:  Xin-Hua Mu; Hai-Xia Shi; Ran An
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

4.  A Systematic Review and Meta-analysis of Clinical Trials of Neuraxial, Intravenous, and Inhalational Anesthesia for External Cephalic Version.

Authors:  Qingzhong Hao; Yirui Hu; Li Zhang; John Ross; Sarah Robishaw; Christine Noble; Xianren Wu; Xiaopeng Zhang
Journal:  Anesth Analg       Date:  2020-12       Impact factor: 6.627

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.